Introduction: Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population.
Box 1. Drug summary

Drug name Apremilast
Phase: EMA approval January 2015. for the treatment of adults with moderate-to-severe plaque psoriasis and psoriasic arthritis Indication Psoriasis; Psoriasic arthritis Pharmacology description/mechanism of action cAMP PDE4 inhibitor
1.INTRODUCTION
Psoriasis is a chronic, inflammatory skin disease, clinically characterized by erythematous and scaly plaques [1] . It affects approximately 2-3 % of the population worldwide. Although the pathogenesis is yet to be fully elucidated, psoriasis is associated with various genetic, immunological, psychological and environmental factors resulting in skin inflammation and keratinocyte proliferation [2, 3] . Psoriatic skin lesions are characterized by hyperproliferation, aberrant differentiation and inflammation, with the psoriatic cytokine network maintained by the crosstalk between immune cells and keratinocytes. In normal skin, this acute inflammatory response signaling is typically down-regulated by negative feedback loops maintaining the homeostatic function of the skin immune system [4] . These feedbacks are altered in psoriatic patients resulting in chronic imbalance of pro-and anti-inflammatory cytokines [5] .
The earliest trigger event seems to be the recruitment of plasmacytoid dendritic cells (pDCs) activated in response to several extracellular self-DNA fragments that get coupled to the endogenous cationic antimicrobial peptides such as LL-37, beta-defensin (hBD)2, hBD3, and lysozyme that are overexpressed in psoriatic skin. The aggregated and condensed structures formed by these peptides and self-DNA breaks innate tolerance via TLR9 activation which leads to IFN-α induction [6] .
LL-37 could also be bound to self-RNA. This compound may activate pDCs through TLR8.
Additionally, mDCs could also be activated directly through TLRs. LL-37 is also recognized as non-self antigen by autoreactive T cells. Alternatively, both pDCs and mDCs could be activated by chemerin, through chemr 23 receptor. IL-26 is a Th17 product that acts as antimicrobial peptide and bound to self DNA it activates TLR9 [7] .
The increased concentration of IFN-α produced by activated pDCs stimulates mDCs and T cells to 17, IL-20) that further promote the pathologic inflammatory cascade [8] . T cells proliferate and differentiate into different T cells subsets, particularly into IL-17-producing T cells [9] . The inflammatory cascade triggers tissue cell response leading to the activation of keratinocytes, fibroblasts, and endothelial cells [10, 11] . The microenvironment within the psoriatic plaque is characterized by an elevated expression of pro-inflammatory and pro-proliferative mediators including cytokines and chemokines that create peculiar inflammatory circuits, which might be therapeutically inhibited, either neutralizing these mediators (i.e., TNF-α, IL-23, and IL-17) or inhibiting intracellular activating signals transduced by PDE4, for instance.
Blocking intracellular transducers that are highly expressed in activated inflammatory cells, such as PDE4 and janus kinase (JAK)-signal transducer and activator of transcription (STAT), it would be possible to inhibit a broader number of cells compared to biologic agents that target a single proinflammatory mediator (i.e., TNF-α). Potentially, interrupting the inflammatory cascade at multiple steps including the earliest phases, could be an effective modulation of the inflammatory gene expression.
OVERVIEW OF THE MARKET
Various topical medications, phototherapy, and systemic drugs are available to treat patients with psoriasis of varying disease severity.
The current gold standard is represented by biologic therapies targeting TNF-α and IL-12/23, which have dramatically improved clinical outcomes in patients with psoriasis. Despite the large number of drugs available, patients with psoriasis are often dissatisfied with those treatments.
Few studies estimated how many patients receive adequate treatments and fewer data is available about patients' satisfaction. Emerging data shows that a large proportion of patients with psoriasis
are not receiving any treatment and almost 30% of patients with moderate-to-severe psoriasis are undertreated, receiving topical medication only [12] . Moreover, there are patients either non-responding to currently available biological agents or have experienced diminishing therapeutic benefit over time [13, 14] .
Although adverse effects and lack of effectiveness are primary reasons for discontinuing biological agents, route of administration, inability to reach specialized centers to obtain adequate assistance are mentioned among the top reasons for discontinuation. 
INTRODUCTION TO THE COMPOUND
During the inflammatory process immune cells belonging to both innate and adaptive immunity are stimulated to produce pro-inflammatory and pro-proliferative mediators, which in turn, induce the activation of tissue cells, especially keratinocytes, fibroblasts and endothelial cells that participate to skin inflammation at lesional sites, secreting pro-inflammatory mediators and sustaining immune cell recruitment [15] . Both immune and tissue cells share a common key transducer for proinflammatory intracellular signaling, represented by the intracellular concentration of cAMP. cAMP is a second messenger involved in numerous cellular functions, including modulation of cytokine production in immune cells [16] . It plays a critical role in transducing extracellular stimuli into intracellular signals, and, thus, in controlling gene expression [17] .
The inflammatory milieu induces G-protein-coupled receptors to bind and activate adenylyl cyclase, which determines increased production of cAMP [18] . High intracellular levels of cAMP increase anti-inflammatory cytokine production via activation of protein kinase A (PKA) and subsequent phosphorylation of transcription factors including CREB (cAMP responsive element binding protein) which is a transcription factor capable of transcribing anti-inflammatory cytokine genes and ATF1 (activating transcription factor-1) [18, 19] . PKA activates CREB by phosphorylation as a result of high intracellular cAMP levels. On the other hand PKA activation leads to inhibition of other transcription factors like NF-κB [20, 21] . Nuclear factor-κB (NF-κB) is a transcription factor that contributes to the expression of proinflammatory cytokines, including TNF-α [10] . It is activated in response to low levels of intracellular cAMP due to decreased competition with CREB for transcriptional factor co-activators [22] .
To summarize, increased level of inflammatory signals are related to low cAMP concentration and vice versa. This has been studied in vitro showing that stimulation of PKA by selective cAMPderived agonists, decrease pro-inflammatory cytokine production from dendritic cells [23] . In most of the immune cell types, including those contributing to psoriasis pathogenesis, intracellular levels of cAMP are tightly controlled by cyclic nucleotide phosphodiesterases (PDEs), which are the only means of degrading cAMP, via enzymatic hydrolysis [22] . There are 11 known subtypes of PDEs that play a key role in degrading cyclic nucleotides (cAMP, cGMP), which are second messengers in intracellular signaling [24] .
CHEMISTRY
dihydro-1H-isoindol-4-yl}acetamide-is an orally available PDE4 inhibitor and non-selective for PDE4 subtypes. With the exception of PDE4, apremilast did not significantly inhibit any of the kinases tested and had no significant activity against any of the cell surface receptors or enzymes tested [22] . Apremilast selectively binds and inhibits PDE4 through the dialkoxyphenyl pharmacophore [25] . This group is shared among several other PDE4i, which have been clinically tested or approved [26, 27] .
PHARMACODYNAMIC ASSESSMENT
Apremilast modulates immune cell activation as PDE4 inhibition reduces the production of proinflammatory mediators like TNF-α, IFN-γ, IL-12/23p40, IL-23p19, IL-17A, and IL-22. On the other hand, apremilast has been reported to increase the production of IL-6, which shows both proand anti-inflammatory features [20, 2828] . Increasing intracellular cAMP levels, apremilast upregulates CREB and down-regulates NF-κB-related genes [29] . It has been shown that apremilast Apremilast pharmacodynamics was assessed in several studies. In early-stage and placebocontrolled studies in subjects with psoriasis, apremilast modulates the expression of inflammatory mediators, as well as demonstrated significant therapeutic activity, and an acceptable tolerability profile. It was estimated an epidermal thickness reduction by a mean of 20.5% from baseline at day 29, using apremilast 20 mg QD [31] . Among responders (subjects with at least 20% reduction in epidermal thickness) T cells were reduced by 28.8% in the dermis and 42.6% in the epidermis. Skin biopsies showed a reduction in the expression of inducible NO synthase (iNOS) mRNA after 2 or 4 weeks of treatment with apremilast. Similarly, in subjects with moderate to severe psoriasis, apremilast reduces keratinocyte responses to inflammation by the reduction in epidermal thickness [31] .
Evaluating the effects of apremilast on LPS-stimulated human peripheral blood mononuclear cells (PBMCs), Schafer et al detected an attenuated expression of LPS-induced proinflammatory cytokines, including TNF-α, IFN-γ, IL-12A and IL-23A with apremilast treatment [32] . Apremilast inhibited expression of genes involved in immune-mediated pathways, including TNF-α, IFN-γ, IL-activation of exchange protein directly activated by cAMP 1 (Epac1), the expression of suppressor of cytokine signaling 3 (SOCS-3), and the inhibition of JAK-STAT signaling [33] .
An open-label phase II study in recalcitrant psoriasis reported that apremilast suppresses MX1 mRNA expression (marker of the type 1 IFNs response in skin lesions) and reduces IFN-α secretion by activated pDCs [34] .
Overall, apremilast seems to act mainly on the innate immune cell compartment (i.e., neutrophils, and NK cells) and, to a lesser extent, on adaptive immune cells. In particular, apremilast does not affect in vivo B-cell activation, as detected in an antigen-specific mouse B-cell transfer model [32] .
Similarly, PDE4 inhibition has no significant effects on keratinocyte proliferation, as well as keratinocyte-derived TNF-α production. Thereby, the reduced cytokine expression derived from the adaptive immune compartment as well as the suppression of keratinocyte proliferation, seems to represent the downstream result of apremilast activity on innate immune cells that are primarily involved in the early stages of psoriasis pathogenesis [32, 35] . concentration of pro-inflammatory products, apremilast was associated with a significant increase in anti-inflammatory mediator production, namely IL-10 and IL-1RA [36] . These outcomes are in line with another study showing the reduced expression of pro-inflammatory genes, namely 12/IL-23p40, IL-17A, and IL-23p19, in lesional skin [34] . The evidence implicates that apremilast has a significant impact on the IL-17 pathway, both systemically (serum level) and locally (lesional skin).
Since, in psoriatic disease, IL-17 is produced not only by T helper cells, but also neutrophils, mast cells, T cells, and innate lymphoid cells, it could be speculated that apremilast treatment may modulate the activity of several immune cells that, producing IL-17, contribute to the psoriatic inflammatory cascade [37] .
PHARMACOKINETICS AND METABOLISM
Absorption: apremilast, orally administered, is absorbed with an absolute bioavailability of ~73%, Metabolism: After oral administration, apremilast is the major circulating component (45%)
followed by its inactive metabolite M12 (39%). In humans, twenty-three apremilast metabolites have been identified and detected in plasma, urine and feces. Both cytochrome (CYP) oxidative metabolism, with subsequent glucuronidation, and non-CYP mediated hydrolysis metabolize apremilast. In vitro, CYP metabolism of apremilast is primarily mediated by CYP3A4, with minor contribution from CYP1A2 and CYP2A6 [38, 39] .
Elimination: The plasma clearance of apremilast is about 10 L/hr in healthy subjects, with a half-life of approximately 6-9 hours. About 58% and 39% is recovered in urine and feces, respectively [40] . The benefits brought by apremilast in the huge panorama of psoriasis therapies is above all in terms of safety: no dose adjustment is necessary in contrast with the conventional medications such as methotrexate or cyclosporine no apremilast-treated patients had TB reactivation, nor worsening of heart failure, no dose adjustment are needed for those subjects with moderate and severe hepatic impairment. Moreover, long-term studies conducted in mice and rats showed no increased risk of apremilast-induced tumors at oral doses up to 8.8 times the maximum recommended human dose 
CONCLUSION
Despite the impressive advancement in treating psoriasis over the past 15 years, there is still need for further improvement. Biologicals and DMARDs have several disadvantages in term of route of administrations and side effects. Moreover, biologicals show increased risks for infections and tumors. Consistent data has demonstrated that apremilast could represent an effective and safe therapeutic tool for the treatment for psoriasis [52] . The value that apremilast adds to the wide panorama of available drugs is represented by the satisfying management of the disease without incurring in severe side effects, the easier route of administration and the opportunity of an effective therapeutic option for those patients unresponsive to both other conventional and biological agents or whose treatment were contraindicated [53, 54] .
In September 2014, apremilast was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and for the treatment of adult patients with active psoriatic arthritis.
EXPERT OPINION
Results from the aforementioned studies show that apremilast inhibits the production of multiple cytokines and chemokines in LPS-stimulated PBMCs such as IFN-γ, MIG, TNF-α, IL-12p70, MIP-1α, MCP-1 and GM-CSF, but not IL-8, IL-1β, promoting the increase of IL-6. The greatest potency was observed against the IFN-dependent chemokines IP-10 and MIG, and IFN-γ itself, suggesting a general selectivity for the interferon responsive genes [55] . Based on the current pathogenic model that identifies the IL-23/IL-17 axis as the main pathway driving the psoriatic plaque formation, apremilast effects on IL-23-and IL-17-producing cells should be more deeply investigated [56, 57] .
Acting on plasmacytoid and myeloid dendritic cells, apremilast seems to interfere with the upstream steps of the IL-23/IL-17 axis, but it would be interesting to define apremilast ability in directly inhibiting IL-17 production.
The pharmacodynamic interaction of apremilast with the immune system cells lead to a broad, but not complete, inhibition of multiple pro-inflammatory mediators: polymorphonuclear leukocytes, mainly neutrophils, were blocked in vitro by apremilast, including the production of IL-8 and LTB4 by polymorphonuclear cells as previously reported for other PDE4 inhibitors [58] . In purified human NK cells, apremilast inhibited production of TNF-α and GM-CSF, and IFN-γ, induced by IL-2 and Fc receptor (FcRγ) cross-linking. Supernatants from psoriatic NK cells have been shown
to produce large amounts of IFN-γ, and to induce expression of ICAM-1 and MHC class II in psoriatic keratinocytes [59] .
Therapeutically, apremilast represent a promising option as it is well-tolerated and no blood test or imaging exam is mandatory during treatment. Another important advantage of apremilast is the route of administration and the possibility to be self-administered, the short half-life also makes apremilast convenient in case of sudden treatment interruption due, for example, to pregnancy or before major surgical intervention [60] . Nevertheless, no data o clinical reports are available regarding safety of apremilast during pregnancy and it is currently labeled as pregnancy category C drug.
Because of the effectiveness in modulating the inflammatory cascade in adaptive and innate immune system and the pharmacokinetic advantages, apremilast may offers an oral treatment option for those patients who discontinue treatments because of ineffectiveness, intolerability, or ineligibility to the currently available drugs.
According with the current armamentarium for the treatment of psoriasis and the efficacy profile, apremilast could be recommended for biologic-naïve patients and in subjects who are contraindicated for any conventional systemic or biologic therapy. Clinical and therapeutic aspects related to the apremilast use still need to be investigated: for instance, its benefits in childhood and adolescence psoriasis. The favorable safety profile leads to consider this drug a possible therapeutic option that could ease the management of these patients. No clinical studies testing apremilast in <18 year-old patients have been performed yet, but, recently, a case of successful treatment with apremilast in a adolescent psoriatic patient has been described, highlighting the noticeable and progressive improvement of the skin lesions and his quality of life associated with a satisfactory safety profile [61] .
However, to place apremilast in the psoriasis therapeutic algorithm, head-to-head trials testing apremilast versus other therapeutics are necessary. 
